HepaRegeniX GmbH

We are excited to welcome Martin Bonde as the new Chair of the Board at HepaRegeniX. With over two decades of experience in biotech and an impressive track record of driving innovation and advancing clinical programs, Dr. Bonde is joining us at a pivotal time as we prepare for our upcoming clinical trials in the USA. At the same time, Elias Papatheodorou moves from his position as Chair of the Board to take on the role of CEO and Managing Director. This transition follows the successful completion of a €15 million Series C financing round, which will fuel the clinical development of our groundbreaking liver regeneration therapy, HRX-215. We are excited about advancing this development to help patients affected by liver failure. Read more in our press release: https://lnkd.in/d77m6zSC   #LiverRegeneration #LiverFailure

We are happy to announce that we successfully raised €15 million in a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and HTGF | High-Tech Gründerfonds. The new funds will be used to support a Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration. Importantly, to take HepaRegeniX through the next stages of clinical development and value creation, Dr. Linda Greenbaum is joining HepaRegeniX as Chief Medical Officer (CMO), who said: “I am honored to join HepaRegeniX at such a critical juncture in its development. With this mode of action, HRX-215 has an immense potential to improve outcomes for patients who are currently not able to undergo potentially curative surgical resections due to liver tumors, and other patient groups affected by liver failure.” Read more in our press release: https://lnkd.in/d7gayikB

We are proud to share that our latest research on our first-in-class MKK4 inhibitor HRX-215 has been featured on the cover of Cell!   This recognizes our exciting findings that HRX-215 can enhance liver regeneration, which is abstracted by the liver fragments originating from a drug capsule. The 3D illustration of the therapeutic target structure MKK4 is a nod to the NMR structure-based approach of drug discovery and development. We would like to thank Stefanie Huber of neunpunktzwei for the cover illustration, which perfectly captures our work.   The full manuscript describing our preclinical as well as our successful first-in-human trial is available here: https://lnkd.in/gke5ukXA #liverdamage #livertransplantation #livertumors

Our publication in Cell, “First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure”, is online!   The research is a collaborative effort between Prof. Dr. Zender’s lab at the Universitätsklinikum Tübingen, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniX. We show that our first-in-class MKK4 inhibitor HRX-215 strongly enhances liver regeneration and prevents liver failure in preclinical model systems.   These results open up new potential treatment avenues in oncological liver surgery and liver transplantation. Our successfully completed Phase I trial further underlines the enormous potential HRX215 has for treating severe liver damage in patients.   Read the full publication here: https://lnkd.in/e787ivmd Our Press release can be found here: https://lnkd.in/dbm-M_uR #liverdamage #livertransplantation #livertumors